Cost-Benefit Evidence For NASA Imaging Tools Needed By Private Sector
This article was originally published in The Gray Sheet
Executive Summary
The costs associated with bringing National Aeronautics and Space Administration-developed imaging technologies to market for medical diagnostic applications could prove a significant obstacle to device industry involvement, industry and academic panelists suggested at a July 18 workshop in Greenbelt, Maryland.
You may also be interested in...
BioLuminate's Smart Probe Breast Cancer Detection Trials Start In Early 2001
San Jose-based BioLuminate expects to be profitable in 2003, immediately following the commercial release of its Smart Probe breast cancer detection diagnostic tool. The privately held start-up began operations in April 2000.
Behavioral Health Company Two Chairs Secures $72M In Equity And Debt Infusion
Two Chairs, which uses algorithms to match the right therapists with patients, secured $72m in investment to expand its business.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.